ADMA Biologics is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.30 – an increase of 11.87% over the previous week. ADMA Biologics employs 624 staff and has a trailing 12-month revenue of around $330.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $21.30 |
|---|---|
| 52-week range | $3.54 - $21.13 |
| 50-day moving average | $17.87 |
| 200-day moving average | $10.97 |
| Wall St. target price | $18.65 |
| PE ratio | 116.5 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $21.37 from 2024-11-20
| 1 week (2024-11-15) | 12.24% |
|---|---|
| 1 month (2024-10-22) | 36.38% |
| 3 months (2024-08-22) | 22.11% |
| 6 months (2024-05-22) | 121.91% |
| 1 year (2023-11-22) | 441.01% |
|---|---|
| 2 years (2022-11-22) | 561.61% |
| 3 years (2021-11-22) | 1,373.79% |
| 5 years (2019-11-22) | 377.01% |
Valuing ADMA Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ADMA Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ADMA Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 117x. In other words, ADMA Biologics shares trade at around 117x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ADMA Biologics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $95.1 million.
The EBITDA is a measure of a ADMA Biologics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $330.2 million |
|---|---|
| Operating margin TTM | 36.57% |
| Gross profit TTM | $35.3 million |
| Return on assets TTM | 15.07% |
| Return on equity TTM | 20.77% |
| Profit margin | 10.53% |
| Book value | $0.81 |
| Market Capitalization | $3.8 billion |
TTM: trailing 12 months
We're not expecting ADMA Biologics to pay a dividend over the next 12 months.
Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $3.54 up to $21.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 0.62. This would suggest that ADMA Biologics's shares are less volatile than average (for this exchange).
ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.